Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA): results of the safety run-in phase
Saved in:
| Main Authors: | , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article (Journal) Editorial |
| Language: | English |
| Published: |
April 2024
|
| In: |
Haematologica
Year: 2024, Volume: 109, Issue: 4, Pages: 1274-1278 |
| ISSN: | 1592-8721 |
| DOI: | 10.3324/haematol.2023.283864 |
| Online Access: | Verlag, lizenzpflichtig, Volltext: https://doi.org/10.3324/haematol.2023.283864 Verlag, lizenzpflichtig, Volltext: https://haematologica.org/article/view/haematol.2023.283864 
|
| Author Notes: | Daniel Heudobler, Florian Luke, Joachim Hahn, Matthias Grube, Pavla Schlosser, Stephan Kremers, Thomas Sudhoff, Jorg Westermann, Marie Luise Hutter-Kronke, Richard F. Schlenk, Daniela Weber, Peter Paschka, Florian Zeman, Hartmut Dohner, Wolfgang Herr, Albrecht Reichle and Simone Thomas |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1904171567 | ||
| 003 | DE-627 | ||
| 005 | 20241205175346.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 241002s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3324/haematol.2023.283864 |2 doi | |
| 035 | |a (DE-627)1904171567 | ||
| 035 | |a (DE-599)KXP1904171567 | ||
| 035 | |a (OCoLC)1475314084 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Heudobler, Daniel |d 1982- |e VerfasserIn |0 (DE-588)1014344204 |0 (DE-627)666277451 |0 (DE-576)34863692X |4 aut | |
| 245 | 1 | 0 | |a Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA) |b results of the safety run-in phase |c Daniel Heudobler, Florian Luke, Joachim Hahn, Matthias Grube, Pavla Schlosser, Stephan Kremers, Thomas Sudhoff, Jorg Westermann, Marie Luise Hutter-Kronke, Richard F. Schlenk, Daniela Weber, Peter Paschka, Florian Zeman, Hartmut Dohner, Wolfgang Herr, Albrecht Reichle and Simone Thomas |
| 264 | 1 | |c April 2024 | |
| 300 | |b Illustrationen | ||
| 300 | |a 5 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 02.10.2024 | ||
| 700 | 1 | |a Luke, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hahn, Joachim |e VerfasserIn |4 aut | |
| 700 | 1 | |a Grube, Matthias |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlosser, Pavla |e VerfasserIn |4 aut | |
| 700 | 1 | |a Kremers, Stephan |e VerfasserIn |4 aut | |
| 700 | 1 | |a Sudhoff, Thomas |e VerfasserIn |4 aut | |
| 700 | 1 | |a Westermann, Jorg |e VerfasserIn |4 aut | |
| 700 | 1 | |a Hutter-Kronke, Marie Luise |e VerfasserIn |4 aut | |
| 700 | 1 | |a Schlenk, Richard Friedrich |d 1965- |e VerfasserIn |0 (DE-588)129025380 |0 (DE-627)387778004 |0 (DE-576)297454102 |4 aut | |
| 700 | 1 | |a Weber, Daniela |e VerfasserIn |4 aut | |
| 700 | 1 | |a Paschka, Peter |e VerfasserIn |4 aut | |
| 700 | 1 | |a Zeman, Florian |e VerfasserIn |4 aut | |
| 700 | 1 | |a Dohner, Hartmut |e VerfasserIn |4 aut | |
| 700 | 1 | |a Herr, Wolfgang |e VerfasserIn |4 aut | |
| 700 | 1 | |a Reichle, Albrecht |e VerfasserIn |4 aut | |
| 700 | 1 | |a Thomas, Simone |e VerfasserIn |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Haematologica |d Pavia : Ferrata Storti Foundation, 2014 |g 109(2024), 4 vom: Apr., Seite 1274-1278 |h Online-Ressource |w (DE-627)814204899 |w (DE-600)2805244-4 |w (DE-576)424051125 |x 1592-8721 |7 nnas |a Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA) results of the safety run-in phase |
| 773 | 1 | 8 | |g volume:109 |g year:2024 |g number:4 |g month:04 |g pages:1274-1278 |g extent:5 |a Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA) results of the safety run-in phase |
| 856 | 4 | 0 | |u https://doi.org/10.3324/haematol.2023.283864 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://haematologica.org/article/view/haematol.2023.283864 |x Verlag |z lizenzpflichtig |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20241002 | ||
| 993 | |a Editorial | ||
| 994 | |a 2024 | ||
| 998 | |g 129025380 |a Schlenk, Richard Friedrich |m 129025380:Schlenk, Richard Friedrich |d 910000 |d 910100 |e 910000PS129025380 |e 910100PS129025380 |k 0/910000/ |k 1/910000/910100/ |p 10 | ||
| 999 | |a KXP-PPN1904171567 |e 458608958X | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"name":{"displayForm":["Daniel Heudobler, Florian Luke, Joachim Hahn, Matthias Grube, Pavla Schlosser, Stephan Kremers, Thomas Sudhoff, Jorg Westermann, Marie Luise Hutter-Kronke, Richard F. Schlenk, Daniela Weber, Peter Paschka, Florian Zeman, Hartmut Dohner, Wolfgang Herr, Albrecht Reichle and Simone Thomas"]},"language":["eng"],"person":[{"family":"Heudobler","role":"aut","display":"Heudobler, Daniel","given":"Daniel"},{"display":"Luke, Florian","given":"Florian","family":"Luke","role":"aut"},{"given":"Joachim","display":"Hahn, Joachim","family":"Hahn","role":"aut"},{"role":"aut","family":"Grube","given":"Matthias","display":"Grube, Matthias"},{"given":"Pavla","display":"Schlosser, Pavla","family":"Schlosser","role":"aut"},{"role":"aut","family":"Kremers","given":"Stephan","display":"Kremers, Stephan"},{"given":"Thomas","display":"Sudhoff, Thomas","family":"Sudhoff","role":"aut"},{"family":"Westermann","role":"aut","display":"Westermann, Jorg","given":"Jorg"},{"family":"Hutter-Kronke","role":"aut","given":"Marie Luise","display":"Hutter-Kronke, Marie Luise"},{"role":"aut","family":"Schlenk","display":"Schlenk, Richard Friedrich","given":"Richard Friedrich"},{"family":"Weber","role":"aut","given":"Daniela","display":"Weber, Daniela"},{"role":"aut","family":"Paschka","given":"Peter","display":"Paschka, Peter"},{"given":"Florian","display":"Zeman, Florian","family":"Zeman","role":"aut"},{"display":"Dohner, Hartmut","given":"Hartmut","role":"aut","family":"Dohner"},{"given":"Wolfgang","display":"Herr, Wolfgang","family":"Herr","role":"aut"},{"family":"Reichle","role":"aut","display":"Reichle, Albrecht","given":"Albrecht"},{"family":"Thomas","role":"aut","display":"Thomas, Simone","given":"Simone"}],"recId":"1904171567","note":["Gesehen am 02.10.2024"],"title":[{"title":"Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA)","subtitle":"results of the safety run-in phase","title_sort":"Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA)"}],"type":{"bibl":"article-journal","media":"Online-Ressource"},"physDesc":[{"noteIll":"Illustrationen","extent":"5 S."}],"id":{"doi":["10.3324/haematol.2023.283864"],"eki":["1904171567"]},"relHost":[{"recId":"814204899","origin":[{"publisherPlace":"Pavia","dateIssuedKey":"2014","dateIssuedDisp":"2014-","publisher":"Ferrata Storti Foundation"}],"title":[{"title_sort":"Haematologica","title":"Haematologica","subtitle":"journal of the European Hematology Association : journal of the Ferrata Storti Foundation"}],"physDesc":[{"extent":"Online-Ressource"}],"id":{"zdb":["2805244-4"],"eki":["814204899"],"issn":["1592-8721"]},"note":["Gesehen am 27.05.2022"],"pubHistory":["99.2014 -"],"language":["eng"],"part":{"text":"109(2024), 4 vom: Apr., Seite 1274-1278","issue":"4","pages":"1274-1278","extent":"5","volume":"109","year":"2024"},"titleAlt":[{"title":"journal of the European Hematology Association"}],"disp":"Low-dose azacitidine, pioglitazone and all-trans retinoic acid is safe in patients aged ≥60 years with acute myeloid leukemia refractory to standard induction chemotherapy (AMLSG 26-16/AML-ViVA) results of the safety run-in phaseHaematologica","type":{"bibl":"periodical","media":"Online-Ressource"}}],"origin":[{"dateIssuedKey":"2024","dateIssuedDisp":"April 2024"}]} | ||
| SRT | |a HEUDOBLERDLOWDOSEAZA2024 | ||